Press Releases

Date Title and Summary Additional Formats  
Toggle Summary Karyopharm and Anivive Lifesciences Sign Exclusive Global License Agreement for Verdinexor for Animal Health Applications
− Anivive Aims to Develop and Commercialize Verdinexor for the Treatment of Cancer in Companion Animals — − Karyopharm to Receive $1 Million Upfront Payment, Then Eligible to Receive Up To $43.5 Million in Future Milestones, Plus Royalties — NEWTON, Mass., May 03, 2017 (GLOBE NEWSWIRE) --
View HTML
Toggle Summary Karyopharm and Ono Pharmaceutical Co. Ltd. Sign Exclusive License Agreement to Develop and Commercialize Selinexor and KPT-8602 in Japan and Other Countries in Asia
− ONO Rights Include Oncology Indications for Selinexor and KPT-8602 in Japan, South Korea, Taiwan, Hong Kong and ASEAN countries — − Karyopharm to Receive ¥2.5 billion (US$22.3 Million) Upfront; Total Deal Value up to Approximately US$193.0 million with Karyopharm Eligible to Receive up to ¥19.15
View HTML
Toggle Summary Karyopharm Announces Management Change
NEWTON, Mass., April 03, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Justin Renz, Executive Vice President, Chief Financial Officer and Treasurer, has stepped down in order to pursue other opportunities,
View HTML
Toggle Summary Karyopharm Announces Partial Clinical Hold to Pause Enrollment in Selinexor Trials
All Currently Enrolled Patients with Stable Disease or Better Can Continue Receiving Selinexor Company Has Amended Investigator's Brochure and Informed Consent Documents as Requested by FDA Company Expects Timelines for Both Ongoing and Planned Studies to Remain Materially Unchanged NEWTON, Mass.,
View HTML
Toggle Summary Karyopharm Announces Presentation of Selinexor and KPT-9274 Clinical Data at the European Society of Medical Oncology 2017 Annual Meeting
Top-line Phase 1 Selinexor Data in Combination with Chemotherapy Show Encouraging Early Efficacy in Patients with Ovarian and Endometrial Cancers Top-line Phase 1 KPT-9274 Data Show a Manageable Safety Profile and Early Signals of Anti-Tumor Activity NEWTON, Mass., Sept.
View HTML
Toggle Summary Karyopharm Announces Results from Interim Analysis of Phase 2 SOPRA Study Evaluating Selinexor in Relapsed/Refractory Acute Myeloid Leukemia
Study Will Not Reach Statistically Significant Improvement in Primary Endpoint of Overall Survival in Patients who are Unfit for Chemotherapy and/or Transplantation ; Patients Deriving Benefit to Remain on Study Clinical Development Continuing in Promising Induction and Combination Settings NEWTON,
View HTML
Toggle Summary Karyopharm Announces Successful Outcome from Phase 2 Portion of Phase 2/3 SEAL Study Evaluating Selinexor in Patients with Previously Treated Advanced Dedifferentiated Liposarcoma
— The Primary Objective of Progression-Free Survival Favored Selinexor over Placebo; Hazard Ratio of 0.60 (RECIST v1.1), Representing a 40% Reduction in Risk of Progression or Death — — Phase 3 Portion of Study Commenced; Expanded to Include North America and Europe and Expected to Enroll Up To 222
View HTML
Toggle Summary Karyopharm Announces the Presentation of New Data at the 2017 American Association for Cancer Research Annual Meeting
Late-Breaking Presentation Highlighting Interim Phase 2b Selinexor Data in Patients with Relapsed or Refractory DLBCL (SADAL Study) Presentations Include Eleven Preclinical Abstracts Describing Key Scientific Findings across the Company's Oncology Programs Overview of Key Selinexor Myeloma Data
View HTML
Toggle Summary Karyopharm Announces the Presentation of Selinexor and KPT-9274 Clinical Data at the European Society of Medical Oncology 2017 Annual Meeting
NEWTON, Mass., Aug. 30, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced two upcoming poster presentations at the European Society of Medical Oncology (ESMO) 2017 Annual Meeting, taking place September 8-12, 2017 in
View HTML
Toggle Summary Karyopharm Appoints Michael Falvey as Chief Financial Officer, Adds New Clinical Strategy and Human Resources Executives and Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
— Michael Falvey, Formerly an Executive at Millennium Pharmaceuticals, Seven Bridges Genomics, Ahura Scientific, and Aspect Medical Systems, Brings 35 Years of Financial and Operational Experience at High Growth Companies — —  Jatin Shah, MD, Formerly Associate Professor and Director of the Myeloma
View HTML